STAT

•

頻道 • 2 個節目

新聞

新聞

17/12/2025更新
商業

商業

每星期更新

06/04/2022

Episode 49: Should gender dysphoria be a required stop en route to gender euphoria?

For trans people who want to receive gender-affirming medical care such as hormone treatments or surgery, one requirement is often a diagnosis of "gender dysphoria," which the Diagnostic and Statistical Manual of Mental Disorders defines as deep psychological distress around one's gender. But not all trans people experience gender dysphoria. Many are just searching for the feeling of gender euphoria. This week, Dallas Ducar discusses issues around gender dysphoria and the need for trans-inclusive providers to take a holistic, person-based approach to care.

06/04/2022

•

35 分鐘
22/11/2023

91: Living in cancer limbo

Fifteen years ago, Mara Buchbinder and colleagues came up with the concept of the “patient in waiting.” The concept described a new category of patients created by cutting-edge testing for conditions that may never appear. The patient in waiting was, quite literally, someone who was waiting to see if they would become ill. Mara's husband, Jesse Summers, was diagnosed with metastatic colon cancer in 2021. It went into remission — but earlier this year, a test searching for disease recurrence came back weakly positive, suggesting that the cancer might be back but might not be. It put Jesse and Mara into a sort of limbo as they waited to see what the result meant.

22/11/2023

•

36 分鐘
06/12/2023

93: Rep. Raul Ruiz on going from the emergency room to Congress

Before he joined Congress, Rep. Raul Ruiz, a Democrat from California, worked in another chaotic environment: the emergency department. Today, he says, he tries to bring his background in medicine and public health to policymaking. In particular, he has turned his attention to a shortage of infectious disease physicians that threatens U.S. preparedness for the next pandemic. Our conversation was based on his recent First Opinion essay, “The infectious disease doctor shortage threatens future pandemic preparedness.” Don’t forget to sign up for the First Opinion newsletter to read each week’s best First Opinion essays.

06/12/2023

•

30 分鐘
16/10/2024

110: Mark Cuban has no doubt he can disrupt health care

Mark Cuban, co-founder of Mark Cuban Cost Plus Drugs, joins the podcast along with STAT's Matthew Herper. They talk with Torie about pharmacy benefit managers, the 2024 presidential campaign, and how the health care industry should work. "This is literally the easiest industry to interrupt, to disintermediate, that I’ve ever been involved with, Cuban said.

16/10/2024

•

37 分鐘
06/06/2024

309: Psychedelics at the FDA, ASCO recap, & MorphoSys update

STAT colleague Meghana Keshavan joins us to dissect Lykos Therapeutics' meeting with an FDA advisory committee. We also discuss the latest news in the health and life sciences, including stories from major biotech conferences. To learn more about Lykos' advisory committee meeting, go here; for more on the tumult at BIO, go here; for a recap of ASCO, go here; to read the latest on Novartis' acquisition of MorphoSys, go here. And you can sign up for Adam’s new newsletter, Biotech Scorecard, here.

06/06/2024

•

30 分鐘
22/02/2024

295: Humira’s legacy, CEO symbolism, and genomic surgery

First, former Alnylam Pharmaceuticals CEO John Maraganore and STAT’s Matthew Herper join us to discuss the legacy of AbbVie chief executive Richard Gonzalez, who announced his retirement this week. Then, we dive into the fascinating world of fetal genome surgery, as STAT’s Megan Molteni joins us to explain the work of a scientist named Tippi MacKenzie. Here's where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe to our newsletter on the business (and secretive inner workings) of the U.S. health care industry, Health Care Inc.

22/02/2024

•

34 分鐘
18/12/2020

Episode 141: Moderna's vaccine milestone, Warp Speed's hurdles, and biotech in 2021

It's the final episode of 2020. We dig into the second vaccine that's been recommended by a panel of FDA advisors, and look ahead to see what's in store for biotech in 2021.

18/12/2020

•

35 分鐘
29/11/2023

92: What we take for granted after 30 years of Prozac

When Prozac first entered the psychiatry scene in in the late 80s, the profession was still Freud's territory. Meaning: it was considered by many a failure to take medication to cure depression. But that was all about to change, with early stewards like psychiatrist Peter Kramer, who refused to shy away from the new drug's potential. These days, he says that people take for granted all of the progress that's been made with antidepressant treatment. Kramer joins Torie to discuss how the country's relationship with antidepressants has changed since the publication of his book "Listening to Prozac." The conversation is based on his First Opinion, "What antidepressants are saying 30 years after the publication of ‘Listening to Prozac.'" Be sure to sign up for the First Opinion newsletter to read each week's best First Opinion essays.

29/11/2023

•

32 分鐘
24/06/2021

Episode 166: FDA inner workings, GSK's foggy future, & the alarming rise in colorectal cancer

First, we sift through the week's news, with a major update from Eli Lilly in Alzheimer's disease and new details on the inner workings of the FDA. Then, STAT's Matthew Herper joins us to discuss how GlaxoSmithKline ended up in a self-preservation struggle. Finally, STAT's Nicholas St. Fleur calls in to talk about the alarming rise of colorectal cancer deaths among young men and his decision to get on an on-camera colonoscopy for a reporting project.

24/06/2021

•

38 分鐘
30/07/2020

Episode 122: Gary Washburn on the NBA bubble, plus a DIY coronavirus vaccine, & behind VC numbers

How much should a Covid-19 vaccine cost? What can basketball teach us about pandemic safety? And just how lucrative is venture capital?

30/07/2020

•

26 分鐘

Voices from the frontiers of health and medicine